medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-10-125-128medsovet-1415Research ArticleУРОЛОГИЯUROLOGYДорипенем в лечении больных с осложненной урологической инфекциейDORIPENEM IN THERAPY OF PATIENTS WITH COMPLICATED UROLOGIC INFECTIONКРИВОБОРОДОВГ. Г.KRIVOBORODOVG. G.

д.м.н., профессор

Москва

MD, Prof.

ТУРЕ. И.TURE. I.

Москва

Российский геронтологический научно-клинический центрРоссияRussian Scientific and Research Center of GerontologyRussian Federation201630122016010125128Copyright © КРИВОБОРОДОВ Г.Г., ТУР Е.И., 20162016КРИВОБОРОДОВ Г.Г., ТУР Е.И.KRIVOBORODOV G.G., TUR E.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1415

На сегодняшний день одной из наиболее распространенных проблем в медицине является антибиотикорезистентность. Это относится как к внутрибольничным (нозокомиальным), так и к внебольничным инфекциям. Данная проблема является общей для экономически развитых стран всего мира и по своей сути должна стоять в одном ряду с вопросами угрозы национальной безопасности. В России ежегодная смертность от нозокомиальной инфекции остается высокой, и, к сожалению, данный показатель год от года не уменьшается [1].

Currently, one of the most common issues in medicine is antibiotics resistance. This relates to nosocomial and to communityacquired infections. This problem is common for economically developed countries of the whole world and in its significance must be placed side by side with issues of the threat to national security. In Russia annual mortality from nosocomial infection remains high and, unfortunately, this indicator doesn’t reduce from year to year [1].

осложненные инфекцииурологические заболеванияантибиотикорезистентностьбета-лактамазыкарбапенемыдорипенемcomplicated infectionsurological diseasesantibiotic resistancebeta-lactamasecarbapenemsdoripenemReferencesЧучалин А.Г., Гельфанд Б.Р. Нозокомиальная пневмония у взрослых: Российские националь ные рекомендации. М.: Компания Боргес. 2009. / Chuchalin A.G., Gelfand B.R. Nosocomial pneumonia in adults: Russian National Recommendations. M.: Borges Company. 2009Чучалин А.Г., Гельфанд Б.Р. Нозокомиальная пневмония у взрослых: Российские националь ные рекомендации. М.: Компания Боргес. 2009. / Chuchalin A.G., Gelfand B.R. Nosocomial pneumonia in adults: Russian National Recommendations. M.: Borges Company. 2009Karam G, Chastre J, Wilcox MH, Vincent JL. Antibiotic strategies in the era of multidrug resistance. Crit Care, 2016 Jun 22, 20(1): 136.Karam G, Chastre J, Wilcox MH, Vincent JL. Antibiotic strategies in the era of multidrug resistance. Crit Care, 2016 Jun 22, 20(1): 136.Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev, 2005, 18: 657-86.Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev, 2005, 18: 657-86.Paterson DL, Ko WC, Von Gottberg A. et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in osocomial Infections. Ann Intern Med, 2004, 140: 26-32.Paterson DL, Ko WC, Von Gottberg A. et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in osocomial Infections. Ann Intern Med, 2004, 140: 26-32.Rodriguez-Bano J, Navarro MD, Romero L et al. Clinical and molecular epidemiology of extended-spectrum betalactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis, 2006, 42: 37-45.Rodriguez-Bano J, Navarro MD, Romero L et al. Clinical and molecular epidemiology of extended-spectrum betalactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis, 2006, 42: 37-45.Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): A global surveillance report (2003). Clin Microbiol Infect, 2005, 11: 974-84.Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): A global surveillance report (2003). Clin Microbiol Infect, 2005, 11: 974-84.Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev, 2007, 20: 440-58.Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev, 2007, 20: 440-58.Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases. Antimicrob. Agents Chemother, 2004, 48: 1313-19.Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases. Antimicrob. Agents Chemother, 2004, 48: 1313-19.Стецюк О.У., Андреева И.В., Козлов Р.С. Новый карбапенемный антибиотик дорипенем: перспективы применения в клинической практике. Клин микробиол антимикроб химиотер, 2008, 10(3): 245-59./Stetsyuk O.U., Andreeva I.V., Kozlov R.S. New carbapenem antibiotic doripenem: prospects of application in clinical practice. Clin Microbiol Antimikrob Chimioter, 2008, 10(3): 245-59.Стецюк О.У., Андреева И.В., Козлов Р.С. Новый карбапенемный антибиотик дорипенем: перспективы применения в клинической практике. Клин микробиол антимикроб химиотер, 2008, 10(3): 245-59./Stetsyuk O.U., Andreeva I.V., Kozlov R.S. New carbapenem antibiotic doripenem: prospects of application in clinical practice. Clin Microbiol Antimikrob Chimioter, 2008, 10(3): 245-59.Norrby SR. Carbapenems. Med Clin North Am, 1995, 79: 745-59.Norrby SR. Carbapenems. Med Clin North Am, 1995, 79: 745-59.Tsuji M, Ishii Y, Ohno A et al. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother, 1998, 42: 94-9.Tsuji M, Ishii Y, Ohno A et al. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother, 1998, 42: 94-9.Iso Y, Irie T, Nishino Y et al. A novel 1-betamethylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidine-3-ylthio)-1 beta-methylcarbapenems. J Antibiot, 1996, 49: 199-209.Iso Y, Irie T, Nishino Y et al. A novel 1-betamethylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidine-3-ylthio)-1 beta-methylcarbapenems. J Antibiot, 1996, 49: 199-209.Bell JM, Fritsche TR, Jones RN, Turnidge JD. Doripenem activity tested against gram- negative pathogens in the Asia-Pacific (APAC) region: Report from the SENTRY Antimicrobial Surveillance Program Antimicrobial Agents and Chemotherapy (ICAAC), American Society for Microbiology, Washington D.C., 2007.Bell JM, Fritsche TR, Jones RN, Turnidge JD. Doripenem activity tested against gram- negative pathogens in the Asia-Pacific (APAC) region: Report from the SENTRY Antimicrobial Surveillance Program Antimicrobial Agents and Chemotherapy (ICAAC), American Society for Microbiology, Washington D.C., 2007.Pillar CM, Aranza-Torres MK, Shah D, Sahm DF. Analysis of doripenem activity, relative to other carbapenems, against target gram-negative pathogens isolated from specific infection sites. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), American Society for Microbiology, Washington D.C., 2007.Pillar CM, Aranza-Torres MK, Shah D, Sahm DF. Analysis of doripenem activity, relative to other carbapenems, against target gram-negative pathogens isolated from specific infection sites. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), American Society for Microbiology, Washington D.C., 2007.Kobayashi Y, Kizaki M, Mutou A. Synergy with S-4661 and vancomycin or teicoplanin against imipenem-resistant MRSA identified by the PCR method. Abstr. F216. In: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C., 1997.Kobayashi Y, Kizaki M, Mutou A. Synergy with S-4661 and vancomycin or teicoplanin against imipenem-resistant MRSA identified by the PCR method. Abstr. F216. In: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); American Society for Microbiology, Washington D.C., 1997.Doribax [package insert]. Raritan, NJ: Ortho- McNeil Pharmaceutical Inc, 2007.Doribax [package insert]. Raritan, NJ: Ortho- McNeil Pharmaceutical Inc, 2007.Shiba K, Nakashima M, Tanimura H et al. Pharmacokinetics and pharmacodyna- mics of S- 4661, new parenteral carbapenem antibiotic. Abstr. F-217. In: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), American Society for Microbiology, Washington D.C., 1997.Shiba K, Nakashima M, Tanimura H et al. Pharmacokinetics and pharmacodyna- mics of S- 4661, new parenteral carbapenem antibiotic. Abstr. F-217. In: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), American Society for Microbiology, Washington D.C., 1997.Floren LC, Wikler MA, Kilfoil T, Ge Y. A phase 1 open-label controlled study to evaluate the safety, tol- erability, and pharmacokinetics (PK) of doripenem (DOR) administered intravenously to subjects with renal impairment. In: Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), American Society for Microbiology, Washington D.C., 2004.Floren LC, Wikler MA, Kilfoil T, Ge Y. A phase 1 open-label controlled study to evaluate the safety, tol- erability, and pharmacokinetics (PK) of doripenem (DOR) administered intravenously to subjects with renal impairment. In: Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), American Society for Microbiology, Washington D.C., 2004.Thye D, Kilfoil T, Leighton A, Wikler M. Doripenem: A phase 1 study to evaluate safety, tolerability and pharmacokinetics in a western healthy volunteer population. Abstr. A-21. In: Program and Abstracts of the 43th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), American Society for Microbiology, Washington D.C., 2003.Thye D, Kilfoil T, Leighton A, Wikler M. Doripenem: A phase 1 study to evaluate safety, tolerability and pharmacokinetics in a western healthy volunteer population. Abstr. A-21. In: Program and Abstracts of the 43th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), American Society for Microbiology, Washington D.C., 2003.Pillar CM, Torres MK, Brown NP et al. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother, 2008 Dec, 52(12): 4388-99.Pillar CM, Torres MK, Brown NP et al. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother, 2008 Dec, 52(12): 4388-99.Справочник Видаль «Лекарственные препараты в России», Москва, Россия. Электронная версия – 2015 г./Vidal Index Drugs in Russia, Moscow, Russia. Electronic version – 2015.Справочник Видаль «Лекарственные препараты в России», Москва, Россия. Электронная версия – 2015 г./Vidal Index Drugs in Russia, Moscow, Russia. Electronic version – 2015.Chastre J, Wunderink R, Prokocimer P et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med, 2008 Apr, 36(4): 1089-96.Chastre J, Wunderink R, Prokocimer P et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med, 2008 Apr, 36(4): 1089-96.Jenkins SG, Fisher AC, Peterson JA, et al. Metaanalysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials. Curr Med Res Opin, 2009 Dec, 25(12): 3029-36.Jenkins SG, Fisher AC, Peterson JA, et al. Metaanalysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials. Curr Med Res Opin, 2009 Dec, 25(12): 3029-36.Lucasti C, Jasovich A, Umeh O et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther, 2008 May, 30(5): 868- 73.Lucasti C, Jasovich A, Umeh O et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther, 2008 May, 30(5): 868- 73.Naber KG, Llorens L, Kaniga K, et al. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother, 2009 Sep, 53(9): 3782-92.Naber KG, Llorens L, Kaniga K, et al. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother, 2009 Sep, 53(9): 3782-92.Singh KP, Li G, Mitrani-Gold FS, Kurtinecz M et al. Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection. AntimicrobSingh KP, Li G, Mitrani-Gold FS, Kurtinecz M et al. Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection. Antimicrobgents Chemother, 2013 Nov, 57(11): 5284-90.gents Chemother, 2013 Nov, 57(11): 5284-90.

The authors declare that there are no conflicts of interest present.